NASDAQ: ACTUActuate Therapeutics Inc Stock
$7.97-0.41 (-4.89%)
Updated Dec 11, 2024
ACTU Price
$7.97
Fair Value Price
N/A
Market Cap
$155.67M
52 Week Low
$5.51
52 Week High
$10.16
P/E
N/A
P/B
29.05x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1.66
Operating Cash Flow
N/A
Beta
1.05
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ACTU's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Value
C
Growth
C
Momentum
B
Sentiment
C
Safety
D
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ACTU
Ranked#97 of 554
Ranked#97 of 554
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $19.53 | A | |
| $6.45 | A | |
| $120.72 | A |
Be the first to know about important ACTU news, forecast changes, insider trades & much more!
ACTU News
Overview
Due Diligence Score
–
Industry Average (23)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ACTU scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ACTU is poor value based on its book value relative to its share price (29.05x), compared to the US Biotechnology industry average (5.62x)
P/B vs Industry Valuation
ACTU's short-term assets ($14.26M) exceed its short-term liabilities ($8.50M)
Short-term Liabilities Financials
ACTU's short-term assets ($14.26M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more ACTU due diligence checks available for Premium users.
Valuation
ACTU price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
29.05x
Industry
5.62x
ACTU is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ACTU's financial health
Profit margin
Revenue
$0.0
Net Income
-$6.0M
Profit Margin
0%
Assets to liabilities
Assets
$14.3M
Liabilities
$8.9M
Debt to equity
1.66
ACTU's short-term assets ($14.26M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ACTU's short-term assets ($14.26M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ACTU's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$9.1M
Investing
$0.0
Financing
$22.3M
ACTU vs Biotech Stocks
Actuate Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.